Eric Padron is an associate member and scientific director of the malignant hematology program at Moffitt Cancer Center. His translational research and clinical practice is focused on MDS/MPNs with a specific interest on identifying novel therapeutic strategies to impact CMML, the most common MDS/MPN subtype.

I am a Physician Scientist with the Division of Hematology and a Professor in the Department of Medicine at the Mayo Clinic (Rochester, MN), with a specific interest in epigenetic dysregulation in age related clonal hematopoiesis of indeterminate potential (CHIP) and ageing-related myeloid neoplasms, specifically Chronic Myelomonocytic Leukemia (CMML). I am the chair of the Acute Leukemia and Chronic Myeloid Neoplasms disease-oriented group and am the Scientific Director of the Center for Individualized Medicine Epigenomics program. I am also the co-director of the Mayo Clinic Comprehensive Cancer Center Precision Genomics Program. CMML is an aggressive malignancy associated with a high morbidity and mortality, and in great need of new treatment options. I have carried out important preclinical and prognostic work in CMML and have importantly demonstrated the prevalence of epigenetic (TET2) and chromatin dysregulation (ASXL1) along with the negative prognostic impact of mutations such as ASXL1. This work has led to the development of the Mayo Molecular Model (Leukemia 2014); a contemporary prognostic model for patients with CMML that now is applied worldwide. In July 2015, I was awarded the NIH CTSA KL-2 scholar award to further my work in CMML and have used this time and mentoring to define the interplay in the genomic and epigenetic landscape of proliferative and dysplastic CMML subtypes (Nature Communications 2021 and 2022). I am the principal investigator of the Mayo Clinic CMML biorepository which has over 750 molecularly annotated patient samples and direct a CMML translational lab currently investigating the genetic and epigenetic profile of CMML, with special emphasis on therapeutics.

In 1996, Prof. Uwe Platzbecker graduated from medical school at the University Hospital “Carl Gustav Carus”, TU Dresden. He proceeded to complete a two-year Postdoctoral Fellowship at the Fred Hutchinson Cancer Research Center, Seattle. In 2012, he became a Professor of Translational Hematology at TU Dresden. Since 2018, Uwe Platzbecker is heading the Hematology program at the University Hospital in Leipzig as Director of the Medical Clinic I, Hematology and Cellular Therapy. His main areas of interest are in the translational exploration of innovative treatment options for patients with hematological malignancies including MDS and AML involving the use of allogenic hematopoietic stem cell transplantation and immunological approaches. Prof. Uwe Platzbecker is also the co-founder and chairman of the European Myelodysplastic Syndromes Cooperative Group (EMSCO) and of the MDS EHA SWG.